We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.345 | 1.24% | 28.155 | 28.26 | 27.94 | 27.94 | 23,208,772 | 19:41:44 |
From May 2019 to May 2024
By Michael Dabaie
Theravance Biopharma Inc. (TBPH) and Pfizer Inc. (PFE) said they entered into a global license agreement for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase, or JAK, inhibitors that can be rapidly metabolized.
Theravance will receive an upfront cash payment of $10 million and will be eligible to receive up to an additional $240 million in development and sales milestone payments from Pfizer.
Theravance will also be eligible to receive royalties on worldwide net sales of any potential products emerging from the program.
JAK inhibitors are currently approved for the treatment of a range of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, myelofibrosis, and ulcerative colitis.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 23, 2019 08:52 ET (13:52 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
